An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer

Gynecologic Oncology

Volumn 134, Issue 2, 2014, Pages 331-337

  Shah, Monjri M ^a   Dobbin, Zachary C ^a   Nowsheen, Somaira ^b   Wielgos, Monica ^b   Katre, Ashwini A ^a   Alvarez, Ronald D ^a   Konstantinopoulos, Panagiotis A ^c   Yang, Eddy S ^b   Landen, Charles N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Homologous recombination deficiency; Ovarian cancer; PARP inhibitor; Rad51

Indexed keywords

HOMOLOGOUS RECOMBINATION DEFICIENCY; OVARIAN CANCER; PARP INHIBITOR; RAD51;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RAD51 RECOMBINASE; TUMOR CELLS, CULTURED;

EID: 84905569979     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.05.009     Document Type: Article

References (33)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics CA Cancer J Clin 64 2014 9 29
2. Ovarian cancer statistics 2012 American Cancer Society [Accessed August 5, 2012, at]
3. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 2003 502 516
4. M.E. Moynahan, J.W. Chiu, B.H. Koller, and M. Jasin Brca1 controls homology-directed DNA repair Mol Cell 4 1999 511 518
5. K.J. Patel, V.P. Yu, and H. Lee et al. Involvement of Brca2 in DNA repair Mol Cell 1 1998 347 357
6. T. Haaf, E.I. Golub, G. Reddy, C.M. Radding, and D.C. Ward Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes Proc Natl Acad Sci U S A 92 1995 2298 2302
7. R. Scully, J. Chen, and R.L. Ochs et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage Cell 90 1997 425 435
8. S.S. Yuan, S.Y. Lee, G. Chen, M. Song, G.E. Tomlinson, and E.Y. Lee BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo Cancer Res 59 1999 3547 3551
9. C. Zhou, P. Huang, and J. Liu The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells Biochem Biophys Res Commun 336 2005 952 960
10. T. Tsuzuki, Y. Fujii, and K. Sakumi et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice Proc Natl Acad Sci U S A 93 1996 6236 6240
11. D.S. Lim, and P. Hasty A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53 Mol Cell Biol 16 1996 7133 7143
12. Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
13. L. Zhao, J.L. Au, and M.G. Wientjes Comparison of methods for evaluating drug-drug interaction Front Biosci (Elite Ed) 2 2010 241 249
14. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 2010 440 446
15. S. Nowsheen, J.A. Bonner, and A.F. Lobuglio et al. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer PLoS One 6 2011 e24148
16. S. Nowsheen, J.A. Bonner, and E.S. Yang The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy Radiother Oncol 99 2011 331 338
17. C.N. Landen Jr., B. Goodman, and A.A. Katre et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer Mol Cancer Ther 9 2010 3186 3199
18. Sanger Institute Cancer Genome Project Accessed February 5, 2014, at http://www.sanger.ac.uk/genetics/CGP/CellLines/ 2014
19. P.A. Konstantinopoulos, D. Spentzos, and B.Y. Karlan et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 2010 3555 3561
20. M. Graeser, A. McCarthy, and C.J. Lord et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 2010 6159 6168
21. S. Domcke, R. Sinha, D.A. Levine, C. Sander, and N. Schultz Evaluating cell lines as tumour models by comparison of genomic profiles Nat Commun 4 2013 2126
22. S.J. Weroha, M.A. Becker, and S. Enderica-Gonzalez et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer Clin Cancer Res 20 2014 1288 1297
23. M.W. Audeh, J. Carmichael, and R.T. Penson et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
24. P.C. Fong, T.A. Yap, and D.S. Boss et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
25. H.A. Risch, J.R. McLaughlin, and D.E. Cole et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 2001 700 710
26. J. Ledermann, P. Harter, and C. Gourley et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
27. K.A. Gelmon, M. Tischkowitz, and H. Mackay et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 2011 852 861
28. A. Mukhopadhyay, A. Elattar, and A. Cerbinskaite et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors Clin Cancer Res 16 2010 2344 2351
29. K.P. Pennington, T. Walsh, and M.I. Harrell et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 2014 764 775
30. N. Chan, I.M. Pires, and Z. Bencokova et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment Cancer Res 70 2010 8045 8054
31. J. Barretina, G. Caponigro, and N. Stransky et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
32. S.A. Forbes, N. Bindal, and S. Bamford et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
33. K.A. Lewis, S. Mullany, and B. Thomas et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance Cancer Res 65 2005 7091 7095